Skip to content
Evigrade
ModerateAntidepressant, norepinephrine-dopamine reuptake inhibitor (NDRI); a separate formulation (Zyntabac) is licensed for smoking cessation×Non-ergot dopamine D2/D3 receptor agonist

Updated · Methodology

Mechanism

Bupropion inhibits the reuptake of dopamine and noradrenaline. In the liver, CYP2B6 converts it mainly into the active metabolite hydroxybupropion, and bupropion itself inhibits CYP2D6 (bupropion SmPC). Pramipexole undergoes little metabolism. The kidneys excrete about 90% of the dose, mostly unchanged, so the documents describe no pharmacokinetic pathway for an interaction (Mirapexin SmPC, European Medicines Agency, EMA). The risk of this combination is linked to dopaminergic action. Bupropion, levodopa and amantadine have dopamine agonist effects, and central nervous system toxicity has been reported when bupropion was combined with levodopa or amantadine. This toxicity is attributed to their cumulative dopamine agonist effects (Wellbutrin XL label, US Food and Drug Administration, FDA). According to its own SmPC, pramipexole is also a dopamine agonist (Mirapexin SmPC, EMA). Both drugs can also cause hallucinations, psychotic symptoms and manic symptoms (bupropion and pramipexole SmPCs).

Symptoms

The documents describe no symptoms specific to this combination. With levodopa or amantadine, bupropion caused restlessness, agitation, tremor, ataxia, gait disturbance, vertigo and dizziness (Wellbutrin XL label, US Food and Drug Administration, FDA). Nausea, vomiting and neuropsychiatric events also occurred (bupropion SmPC). The most common adverse reactions of pramipexole are nausea, dyskinesia, hypotension, dizziness, somnolence, insomnia, constipation, hallucinations, headache and fatigue. Sudden sleep episodes during the day can also occur (Mirapexin SmPC, European Medicines Agency, EMA). The most common adverse reactions of bupropion are insomnia, headache, dry mouth, nausea and vomiting. Bupropion can raise blood pressure, and its seizure risk rises with the dose (bupropion SmPC).

Management

No document contraindicates the combination. Use bupropion with caution together with levodopa or amantadine. Central nervous system toxicity has been reported with these combinations and is attributed to cumulative dopamine agonist effects (bupropion SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; Wellbutrin XL label, US Food and Drug Administration, FDA). Pramipexole is also a dopamine agonist (Mirapexin SmPC, European Medicines Agency, EMA), although the documents do not name this pair directly. Tell the patient that hallucinations may occur. Monitor regularly for mania and delirium, and if they develop, consider a lower pramipexole dose or gradual discontinuation (Mirapexin SmPC, EMA). Stop bupropion if delusions, hallucinations, psychosis or other neuropsychiatric reactions occur (Wellbutrin XL label, FDA). Do not exceed the recommended bupropion dose, because the seizure risk is dose-related (bupropion SmPC, AEMPS). People who have had somnolence or a sudden sleep episode on pramipexole should not drive. For them, consider a lower dose or stopping pramipexole (Mirapexin SmPC, EMA). Measure blood pressure at the start of bupropion treatment and monitor it afterwards (bupropion SmPC, AEMPS). With pramipexole, monitor blood pressure, especially at the start of treatment, because of the risk of orthostatic hypotension (Mirapexin SmPC, EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Bupropion

Other interactions with Pramipexole